Richard D. Truesdell, Jr.
Lawyers
Filters
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…
Focus Financial Partners Inc. $615.4 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $615.4 million initial public offering of 18,648,649 shares of Class A common stock of Focus Financial…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…
Davis Polk Advises IHS Markit Ltd. on Its $1.25 Billion Senior Notes Offering
Davis Polk advised IHS Markit Ltd. in connection with its SEC-registered offering of $1.25 billion aggregate principal amount of senior notes in two series, consisting of $500 million…
Wix.com Ltd. $385 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Wix.com Ltd. of $385 million aggregate principal amount of its 0%…
Charah Solutions, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of Charah Solutions, Inc., which consisted of 7,352,941 shares of…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…
Valero Energy Corporation $750 Million Senior Notes Offering
Davis Polk advised the joint book-running managers on an SEC-registered offering by Valero Energy Corporation of $750 million aggregate principal amount of its 4.350% senior notes due…
Iterum Therapeutics plc Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with Iterum Therapeutics plc’s initial public offering of 6,150,000 ordinary shares, at $13.00 per…
Calyxt, Inc. Common Stock Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 4,057,500 shares of common stock of Calyxt, Inc., including 457,500…